Page last updated: 2024-09-03

reboxetine and Depression

reboxetine has been researched along with Depression in 54 studies

Research

Studies (54)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (5.56)	18.2507
2000's	20 (37.04)	29.6817
2010's	25 (46.30)	24.3611
2020's	6 (11.11)	2.80

Authors

Authors	Studies
Belloch, FB; Cortés-Erice, M; Díaz-Perdigon, T; Herzog, E; Puerta, E; Tordera, RM; Zhang, XM	1
Keidan, L; Pick, CG; Schreiber, S	1
Becker, GA; Haars, S; Hesse, S; Hoffmann, KT; Lobsien, D; Luthardt, J; Rullmann, M; Sabri, O; Schinke, C; Schmidt, E; Stoppe, M; Then Bergh, F	1
Gougoulaki, M; Lewis, G; Nutt, DJ; Peters, TJ; Wiles, NJ	1
Chmielarz, P; Chorązka, K; Kowalska, M; Kuśmierczyk, J; Nalepa, I; Rafa-Zabłocka, K; Satała, G	1
Gao, S; Miao, D; Qian, J; Shi, W; Wu, Z; Xu, H; Zhang, X	1
Bove, M; Mhillaj, E; Morgese, MG; Schiavone, S; Trabace, L; Tucci, P	1
Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C	1
Artigas, F; Bortolozzi, A; Ferrés-Coy, A; Fullana, MN; Meana, JJ; Ortega, JE; Paz, V; Ruiz-Bronchal, E	1
Bogatko, K; Doboszewska, U; Dudka, J; Poleszak, E; Serefko, A; Świąder, K; Szopa, A; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A; Wyska, E	1
Berezniuk, I; Biswas, R; Creson, TK; Fricker, AD; Fricker, LD; Rodriguiz, RM; Wetsel, WC; Wilkins, JJ	1
De Bundel, D; DuPont, CM; Feltmann, K; Femenía, T; Konradsson-Geuken, Å; Lindskog, M; Schilström, B	1
Charoenphandhu, J; Charoenphandhu, N; Lapmanee, S	1
Button, KS; Crawford, A; Green, A; Lewis, G; Nutt, D; Peters, TJ; Wiles, N	1
Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J	1
Bhagya, V; Raju, TR; Shankaranarayana Rao, BS; Srikumar, BN	1
Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W	1
Dudka, J; Kasperek, R; Nowak, G; Poleszak, E; Serefko, A; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A	1
Gaweł, M; Młyniec, K; Nowak, G	1
Rahman, S; Roni, MA	1
Dong, C; Han, M; Hashimoto, K; Ma, M; Ren, Q; Saito, R; Yang, C; Yao, W; Zhang, JC	1
Andreasen, JT; Olsen, GM; Redrobe, JP; Wiborg, O	1
Bootzin, E; Millan, MJ; O'Donnell, JM; Zhang, HT; Zhao, Z	1
Assem-Hilger, E; Kasper, S; Konstantinidis, A; Pjrek, E; Praschak-Rieder, N; Willeit, M; Winkler, D	1
Ayres, R; Cowen, PJ; Favaron, E; Goodwin, GM; Harmer, CJ; Massey-Chase, R; O'Sullivan, U; Reinecke, A	1
Enkel, T; Gass, P; Gholizadeh, D; Hurlemann, R; Sanchis-Segura, C; Spanagel, R; Vollmayr, B; von Bohlen Und Halbach, O	1
Deuschle, M; Gilles, M; Lederbogen, F; Paslakis, G; Scharnholz, B; Schilling, C	1
Bert, B; Fink, H; Günther, L; Millan, MJ; Rex, A; Rothe, J; Voigt, JP	1
Arolt, V; Cerovecki, A; Dehning, S; Müller, N; Musil, R; Riedel, M; Schwarz, MJ; Spellmann, I	1
Barbato, A; Bortolotti, A; D'Avanzo, B; Fortino, I; Franchi, C; Merlino, L; Nobili, A; Parabiaghi, A; Tettamanti, M	1
Fang, TH; Ku, YC; Liu, YP; Lo, SM; Tsai, YJ; Tung, CS	1
Artigas, F; Bortolozzi, A; Castañé, A; Masana, M; Santana, N	1
Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N	1
Corbo, M; Fiori, F; Martinotti, G; Sepede, G	1
Berrocoso, E; Mico, JA; Miguelez, C; Ugedo, L	1
De Risio, S; Della Marca, G; Di Giannantonio, M; Farina, B; Mazza, S; Mennuni, G	1
Brunello, N; Kasper, S; Leonard, B; Mendlewicz, J; Montgomery, S; Nelson, J; Paykel, E; Racagni, G; Versiani, M	1
Kodesh, A; Kretzmer, G; Lerner, AG; Shufman, E; Sigal, M	1
Mohr, N; Muller, JE; Seedat, S; Stein, DJ; van Rheede van Oudtshoorn, E	1
Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA	1
Bodlund, O; Häggström, L	1
Lambert-Baumann, J; Messer, T; Schmauss, M	1
Leon, AC; Nelson, JC; Portera, L	2
Abumaria, N; Flügge, G; Fuchs, E; Havemann-Reinecke, U; Hiemke, C; Rüther, E; Rygula, R; Zernig, G	1
Connor, TJ; Dredge, K; Harkin, A; Kelly, JP; Leonard, BE; McNamara, M; Redmond, A	1
Souery, D; Sternon, J	1
Devarajan, S; Dursun, SM	1
Dencker, SJ	1
Blier, P; Szabo, ST	1
Berk, M; Schutz, G	1
Caraceni, T; Eichhorn, T; Girotti, F; Höglinger, GU; Krieg, JC; Oertel, WH; Poewe, W; Spottke, AE	1

Reviews

7 review(s) available for reboxetine and Depression

Article	Year
Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. Journal of psychiatric research, 2009, Volume: 43, Issue:8 Topics: Adrenergic Uptake Inhibitors; Citalopram; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Humans; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Seasonal Affective Disorder; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome	2009
Citalopram versus other anti-depressive agents for depression. The Cochrane database of systematic reviews, 2012, Jul-11, Issue:7 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Humans; Morpholines; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride	2012
Reboxetine in clinical practice: a review. La Clinica terapeutica, 2012, Volume: 163, Issue:4 Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Depression; Humans; Morpholines; Reboxetine; Sleep Wake Disorders	2012
The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2002, Volume: 12, Issue:5 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Catechol O-Methyltransferase; Depression; Humans; Imipramine; Monoamine Oxidase; Morpholines; Norepinephrine; Reboxetine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tyrosine 3-Monooxygenase	2002
Reboxetine--another new antidepressant. Drug and therapeutics bulletin, 1998, Volume: 36, Issue:11 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depression; Humans; Morpholines; Randomized Controlled Trials as Topic; Reboxetine	1998
The need for new and better antidepressants: reboxetine a new option. Acta psychiatrica Scandinavica. Supplementum, 2000, Volume: 402 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Drug Interactions; Humans; Morpholines; Norepinephrine; Reboxetine; Social Adjustment	2000
Depression in Parkinson's disease. An update. Advances in neurology, 2001, Volume: 86 Topics: Adrenergic Uptake Inhibitors; Depression; Humans; Morpholines; Parkinson Disease; Reboxetine	2001

Trials

10 trial(s) available for reboxetine and Depression

Article	Year
Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:8 Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Depression; Female; Humans; Male; Menopause; Middle Aged; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome	2021
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:6 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Psychiatric Status Rating Scales; Reboxetine; Risperidone; Schizophrenia; Schizophrenic Psychology	2014
Effect of acute antidepressant administration on negative affective bias in depressed patients. The American journal of psychiatry, 2009, Volume: 166, Issue:10 Topics: Adolescent; Adult; Affect; Antidepressive Agents; Anxiety Disorders; Depression; Depressive Disorder; Emotions; Facial Expression; Female; Humans; Male; Memory; Middle Aged; Morpholines; Personality; Personality Inventory; Reboxetine; Recognition, Psychology; Visual Perception	2009
The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. European archives of psychiatry and clinical neuroscience, 2011, Volume: 261, Issue:3 Topics: Adult; Analysis of Variance; Antidepressive Agents; Depression; Female; Humans; Inpatients; Male; Metabolic Diseases; Middle Aged; Morpholines; Reboxetine; Time Factors	2011
Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. Journal of affective disorders, 2011, Volume: 134, Issue:1-3 Topics: Adult; Aged; Antidepressive Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Depression; Depressive Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Psychological Tests; Pyrazoles; Reboxetine; Sulfonamides; Transforming Growth Factor beta; Young Adult	2011
The effects of reboxetine on human sleep architecture in depression: preliminary results. Journal of affective disorders, 2002, Volume: 71, Issue:1-3 Topics: Adult; Antidepressive Agents; Depression; Electroencephalography; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Sleep Wake Disorders	2002
Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. International clinical psychopharmacology, 2003, Volume: 18, Issue:5 Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Citalopram; Comorbidity; Cross-Over Studies; Depression; Female; Humans; Male; Middle Aged; Morpholines; Panic Disorder; Pilot Projects; Reboxetine; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome	2003
Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biological psychiatry, 2005, Jun-15, Volume: 57, Issue:12 Topics: Adrenergic Uptake Inhibitors; Adult; Depression; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Placebos; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2005
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11 Topics: Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Depression; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Libido; Male; Morpholines; Norepinephrine; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Sexual Dysfunctions, Psychological; Sleep Wake Disorders; Treatment Outcome	2005
Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. International clinical psychopharmacology, 2001, Volume: 16, Issue:5 Topics: Adult; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2001

Other Studies

37 other study(ies) available for reboxetine and Depression

Article	Year
Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons. Progress in neuro-psychopharmacology & biological psychiatry, 2023, 03-08, Volume: 121 Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Glutamic Acid; Ketamine; Mice; Neurons; Prefrontal Cortex; Reboxetine; Vesicular Glutamate Transport Protein 1	2023
Treatment-Resistant Depression (TRD): Is the Opioid System Involved? International journal of molecular sciences, 2023, Jul-06, Volume: 24, Issue:13 Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Mianserin; Mice; Mirtazapine; Moclobemide; Naloxone; Reboxetine; Trazodone; Venlafaxine Hydrochloride	2023
Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients. Scientific reports, 2020, 09-04, Volume: 10, Issue:1 Topics: Adult; Brain; Carbon Radioisotopes; Depression; Disability Evaluation; Fatigue; Female; Humans; Immunotherapy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Psychiatric Status Rating Scales; Reboxetine; Young Adult	2020
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro. International journal of molecular sciences, 2021, May-01, Volume: 22, Issue:9 Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Regulation; Humans; Imipramine; Mianserin; Mice; PC12 Cells; Rats; Reboxetine; Receptors, Adrenergic, alpha-1; Signal Transduction	2021
Promoting the hippocampal PPARα expression participates in the antidepressant mechanism of reboxetine, a selective norepinephrine reuptake inhibitor. Behavioural brain research, 2022, 01-07, Volume: 416 Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Depression; Hippocampus; Male; Mice; Mice, Inbred C57BL; PPAR alpha; Reboxetine	2022
Antidepressant drugs for beta amyloid-induced depression: A new standpoint? Progress in neuro-psychopharmacology & biological psychiatry, 2017, 08-01, Volume: 78 Topics: Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; Immobility Response, Tonic; Ketamine; Male; Morpholines; Nerve Growth Factor; Norepinephrine; Rats; Reboxetine; Serotonin	2017
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ open, 2017, Aug-03, Volume: 7, Issue:8 Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome	2017
Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression. Molecular neurobiology, 2019, Volume: 56, Issue:4 Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Down-Regulation; Gene Knockdown Techniques; Male; Mice, Inbred C57BL; Neurons; Norepinephrine; Potassium Channels; Reboxetine; RNA, Small Interfering; Serotonergic Neurons; Serotonin; Sertraline	2019
DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests. Naunyn-Schmiedeberg's archives of pharmacology, 2018, Volume: 391, Issue:12 Topics: Adenosine A1 Receptor Antagonists; Animals; Antidepressive Agents; Brain; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Hindlimb Suspension; Imipramine; Male; Mice; Motor Activity; Reboxetine; Serotonin Antagonists; Xanthines	2018
Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice. The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:7 Topics: Age Factors; Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Carboxypeptidase H; Depression; Diazepam; Exploratory Behavior; Hindlimb Suspension; Maze Learning; Mice; Mice, Transgenic; Morpholines; Motor Activity; Obesity; Point Mutation; Reboxetine; Swimming	2013
Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine. The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:9 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Cognition; Depression; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Hippocampus; Male; Morpholines; Motor Activity; Nootropic Agents; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Dopamine D1; Receptors, Dopamine D5; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Swimming; Time Factors	2013
Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors. Behavioural brain research, 2013, Aug-01, Volume: 250 Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanols; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Male; Maze Learning; Morpholines; Physical Conditioning, Animal; Rats; Rats, Wistar; Reboxetine; Restraint, Physical; Running; Stress, Psychological; Sucrose; Swimming; Venlafaxine Hydrochloride	2013
Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. Journal of affective disorders, 2014, Volume: 163 Topics: Adult; Antidepressive Agents; Citalopram; Depression; Female; Humans; Linear Models; Male; Middle Aged; Morpholines; Prognosis; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Reboxetine; Treatment Outcome	2014
The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. Journal of neuroscience research, 2015, Volume: 93, Issue:1 Topics: Acetylcholinesterase; Animals; Animals, Newborn; Antidepressive Agents; Biogenic Monoamines; Depression; Disease Models, Animal; Electric Stimulation; Female; Food Preferences; Hippocampus; In Vitro Techniques; Learning Disabilities; Male; Morpholines; Neuronal Plasticity; Rats; Rats, Wistar; Reboxetine; Spatial Learning; Swimming	2015
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2014, Volume: 65, Issue:5 Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; Imipramine; Male; Mice; Morpholines; Reboxetine; Sodium Chloride; Zinc	2014
The effects of ifenprodil on the activity of antidepressant drugs in the forced swim test in mice. Pharmacological reports : PR, 2014, Volume: 66, Issue:6 Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Synergism; Fluoxetine; Imipramine; Mice; Morpholines; Piperidines; Reboxetine; Swimming; Thiazepines	2014
Study of antidepressant drugs in GPR39 (zinc receptor⁻/⁻) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists. Behavioural brain research, 2015, Volume: 287 Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Imipramine; Ketamine; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Motor Activity; Psychological Tests; Reboxetine; Receptors, G-Protein-Coupled; Receptors, N-Methyl-D-Aspartate; Swimming	2015
Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice. Pharmacology, biochemistry, and behavior, 2015, Volume: 139, Issue:Pt A Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Immobility Response, Tonic; Lobeline; Male; Mice; Morpholines; Reboxetine	2015
Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacology, biochemistry, and behavior, 2016, Volume: 144 Topics: Animals; Behavior, Animal; Citalopram; Depression; Interleukin-10; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Morpholines; Reboxetine; Tumor Necrosis Factor-alpha	2016
Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:7 Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Female; Mice; Mice, Inbred Strains; Morpholines; Motor Activity; Nicotinic Agonists; Nicotinic Antagonists; Reboxetine	2009
Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:6 Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Cyclohexanols; Depression; Down-Regulation; Fenclonine; Male; Monoamine Oxidase Inhibitors; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Protein Synthesis Inhibitors; Protriptyline; Rats; Rats, Sprague-Dawley; Reboxetine; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Sertraline; Venlafaxine Hydrochloride	2009
Ambiguous-cue interpretation is biased under stress- and depression-like states in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010, Volume: 35, Issue:4 Topics: Adrenergic Uptake Inhibitors; Amygdala; Analysis of Variance; Animals; Behavior, Animal; Bias; Conditioning, Psychological; Corticosterone; Cross-Over Studies; Cues; Depression; Discrimination, Psychological; Disease Models, Animal; Extinction, Psychological; Feeding Behavior; Food Preferences; Hippocampus; Male; Morpholines; Proto-Oncogene Proteins c-fos; Rats; Reboxetine; Stress, Psychological	2010
5-HT(1A)-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test. Neuropharmacology, 2011, Volume: 61, Issue:3 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Citalopram; Depression; Female; Limbic System; Male; Mice; Mice, Transgenic; Morpholines; Motor Activity; Nerve Tissue Proteins; Neurons; Organ Specificity; Reboxetine; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Agonists; Sex Characteristics	2011
The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:2 Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Morpholines; Paroxetine; Pharmacoepidemiology; Practice Patterns, Physicians'; Publication Bias; Reboxetine; Selective Serotonin Reuptake Inhibitors	2012
Different involvement of ventral and dorsal norepinephrine pathways on norepinephrine reuptake inhibitor-induced locomotion and antidepressant-like effects in rats. Neuroscience letters, 2012, Apr-18, Volume: 514, Issue:2 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depression; Hippocampus; Locus Coeruleus; Male; Morpholines; Motor Activity; Neural Pathways; Norepinephrine; Rats; Rats, Sprague-Dawley; Reboxetine; Swimming	2012
Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies. Neuropharmacology, 2012, Volume: 63, Issue:4 Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Brain-Derived Neurotrophic Factor; Depression; Dopamine; Drug Synergism; Drug Therapy, Combination; Extracellular Fluid; Gene Expression Regulation; Male; Mianserin; Mirtazapine; Morpholines; Organ Specificity; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Reboxetine; RNA, Messenger	2012
L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats. Neuropharmacology, 2013, Volume: 67 Topics: Animals; Antidepressive Agents; Contraindications; Depression; Drug Therapy, Combination; Fluoxetine; Levodopa; Locus Coeruleus; Male; Morpholines; Motor Activity; Rats; Rats, Sprague-Dawley; Reboxetine; Treatment Outcome	2013
LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report. The Israel journal of psychiatry and related sciences, 2002, Volume: 39, Issue:2 Topics: Adrenergic Uptake Inhibitors; Adult; Depression; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Morpholines; Reboxetine; Severity of Illness Index	2002
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2004, May-25, Volume: 101, Issue:21 Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail	2004
[SSRI resistant depression. Supplementation with noradrenergic pharmaceuticals can be a good alternative]. Lakartidningen, 2004, Sep-02, Volume: 101, Issue:36 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depression; Drug Resistance; Drug Therapy, Combination; Female; Humans; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors	2004
Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice. CNS drugs, 2005, Volume: 19, Issue:1 Topics: Antidepressive Agents; Demography; Depression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Morpholines; Personality Inventory; Practice Guidelines as Topic; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Reboxetine; Time Factors; Treatment Outcome	2005
Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. Behavioural pharmacology, 2008, Volume: 19, Issue:3 Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Morpholines; Motivation; Motor Activity; Rats; Rats, Wistar; Reboxetine; Reward; Stress, Psychological	2008
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. European journal of pharmacology, 1999, Jan-08, Volume: 364, Issue:2-3 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Analgesics; Animals; Antidepressive Agents; Body Temperature; Clonidine; Depression; Disease Models, Animal; Drug Therapy, Combination; Exploratory Behavior; Hydroxyindoleacetic Acid; Male; Morpholines; Motor Activity; Olfactory Bulb; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin Receptor Agonists; Sertraline; Swimming	1999
[Reboxetine (Edronax)]. Revue medicale de Bruxelles, 1999, Volume: 20, Issue:6 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depression; Drug Combinations; Drug Interactions; Humans; Morpholines; Reboxetine; Safety; Social Adjustment; Time Factors	1999
Citalopram plus reboxetine in treatment-resistant depression. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:5 Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2000
Depression. Five new treatments. Harvard health letter, 2000, Volume: 25, Issue:11 Topics: Antidepressive Agents; Depression; Depressive Disorder; Electric Stimulation Therapy; Humans; Hydrocortisone; Magnetics; Morpholines; Reboxetine; Substance P; Vagus Nerve	2000
Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. The European journal of neuroscience, 2001, Volume: 13, Issue:11 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Clonidine; Depression; Dose-Response Relationship, Drug; Indophenol; Locus Coeruleus; Male; Morpholines; Norepinephrine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Reboxetine; Serotonin; Serotonin Receptor Agonists	2001